Auro Laboratories Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 263.95 as of 12 Jun 15:30 . The P/E Ratio of Auro Laboratories Ltd changed from 7 on March 2021 to 78.2 on March 2025 . This represents a CAGR of 62.04% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 years The Market Cap of Auro Laboratories Ltd changed from ₹ 50.55 crore on March 2021 to ₹ 143.69 crore on March 2025 . This represents a CAGR of 23.24% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 years The revenue of Auro Laboratories Ltd for the Sep '25 is ₹ 9.81 crore as compare to the Jun '25 revenue of ₹ 3.19 crore. This represent the growth of 207.52% The revenue of Jagsonpal Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Auro Laboratories Ltd for the Sep '25 is ₹ 3.33 crore as compare to the Jun '25 ebitda of ₹ 0.45 crore. This represent the growth of 640% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0.72 crore over 4 quarters. This represents a CAGR of -4.00% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

FAQs for the comparison of Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of Auro Laboratories Ltd is 164 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,387 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd?

As of June 15, 2026, the Auro Laboratories Ltd stock price is INR ₹263.95. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹210.8.

How do dividend payouts of Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.